在极低出生体重的婴儿和神经发育到学龄的儿童中,总用皮松剂量
Akinobu Taniguchi1, Basile Chrétien2, Takashi Maeda3
1Division of Neonatology, Center for Maternal-Neonatal Care, Nagoya University Hospital, Nagoya, Japan. akinobut7@nagoya-u.jp.
Pediatric research
|September 23, 2025
概括
在极低出生体重 (ELBW) 婴儿中,较高的皮 (HC) 剂量与较低的发育和智力系数 (DQ/IQ) 得分有关,这种趋势持续到学龄. 这突显了HC治疗对神经发育的潜在剂量依赖性影响.
科学领域:
- 新生儿医学 新生儿医学
- 儿科神经学 儿科神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 在极低出生体重 (ELBW) 婴儿中,皮 (HC) 对神经发育的长期影响尚未完全理解.
- HC被用作替代德克萨米他用于ELBW婴儿的葡萄糖皮质类药物治疗.
研究的目的:
- 调查新生儿总皮松 (HC) 剂量与ELBW婴儿中学龄前神经发育结果之间的关联.
- 为了确定HC对神经发育的影响是否依赖于剂量并随时间持续.
主要方法:
- 在八个日本中心进行了一项回顾性的纵向队列研究.
- 包括2015年至2017年间出生的ELBW婴儿.
- 分析了高达36周的月经后年龄的HC总剂量与评估到学龄的神经发育结果.
主要成果:
- 较高的总HC剂量与较低的发育和智力系数 (DQ/IQ) 分数显著相关.
- 这种关联在6岁时仍然存在,这表明对认知结果的持续影响.
- 对于每增加10毫克的HC剂量,智商得分下降了2.82分 (p=0.001).
结论:
- 在ELBW婴儿的新生儿HC总剂量和长期DQ/IQ得分之间存在显著的关系.
- 临床医生在治疗ELBW婴儿时应考虑HC的潜在剂量依赖的神经发育影响.
- 这些发现强调了在这个脆弱人群中仔细管理HC剂量的重要性.
相关概念视频
Drug Dosing: Infants and Children
256
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
256
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
439
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
439
Pharmacokinetics in Pediatric Patients: Drug Excretion
212
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
212
Factors Affecting Drug Response: Overview
3.0K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
3.0K
Pharmacokinetics in Pediatric Patients: Drug Distribution
254
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
254
Dosage Regimen: Individualization
166
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
166


